

References

- Agarwal R, Acharya M, Tian J, Melnich JZ, Qiu P(2005):*** Antiproteinuric effect of oral paricalcitol in chronic kidney disease. *Kidney Int.*68(6):2823-8.
- Akiba T (2007):*** New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure. *Clin Calcium.* May;17(5):767-71.
- Albaaj F, Hutchison A (2003):*** Hyperphosphatemia in renal failure : causes, consequences and current management. *Drugs;* 63(6):577-96.
- Al-Hejaili F, Kortas C, Leitch R, Heidenheim AP, Clement L, Nesrallah G, Lindsay RM(2003):*** Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. *J Am Soc Nephrol* 14 : 2322 –2328.
- Amiel C, Kuntziger H, Couette S, Coureau C and Bergounioux N (2007):*** Evidence for a parathyroid hormone-independent calcium modulation of phosphate transport along the nephron. *Journal of Clinical Investigation;* 57,256-63.
- Arenas MD, Alvarez-Ude F, Gil MT, Moledous A, Malek T, Nunez C (2007):*** Implementation of 'K/DOQI clinical practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic

haemodialysis. *Nephrol Dial Transplant*;3,178-179.

Ayus JC, Mizani MR, Achinger SG, et al (2005): Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective controlled study. *J Am Soc Nephrol* ; 16:2778-2788.

Badves SV, Zimmermann DL, Knoll GA, et al (2008): Peritoneal phosphate clearance is influenced by peritoneal dialysis modality, independent of peritoneal transport characteristic. *Clin Soc Nephrol* ; 3:1711-1717.

Baker SB, Worthly LI (2002): The essentials of calcium, magnesium and phosphate metabolism: Part 1 physiology. *Crit care resusc.* 4:301-306.

Bammens B, Evenepoel P, Verbvenke K, Vanrenterghem Y(2003): Removal of middle molecules and protein bound solutes by peritoneal dialysis and relation with uremic symptoms. *Kidney Int*; 64: 2238-2243.

Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y (2005): Time profile of Peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients. *Am J Kidney Dis* : 46-512-519.

Behets GJ, Dams G, Damment S, Damment SJ, Bouillon R, De Broe ME, D'Haese PC (2004a): Does the phosphate binder lanthanum carbonate affect bone in chronic renal failure rats? *J Am Soc Nephrol* 15 : 2219–2228.

Behets GJ, Gritters M, Dams G, De Broe ME, D'Haese PC (2004b): Effects of efficient phosphate binding on bone histology in chronic renal failure rats. [Abstract]. *J Am Soc Nephrol* 15 : 271A .

Bilezikian JP, Potts JT Jr, El-Hajj Fuleihan G, Kleerekoper M, Neer R, Peacock M, Rasad J, Silverberg SJ, Udelsman R & Wells SA (2002): Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. *Journal of Bone and Mineral Research* 17 (Suppl 2) N2–N12. .

Block GA and Port FK (2000): Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. *Am J Kidney Dis*; 35:1226-1237.

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM(2004): Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. *J Am Soc Nephrol* 15 : 2208–2218.

- Block GA, Marin KJ, DeFrancisco ALM, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG (2004):** Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. *N Engl J Med* 350 : 1516–1525.
- Block GA, Spiegel DM and Ehrlich J (2005):** Renagel in New Dialysis Study: Mean serum calcium level. *Kidney Int*; 68:1815-1824.
- Borzecki AM, Lee A and Kazis LA (2007):** Survival in end stage renal disease: calcium carbonate vs. sevelamer. *J Clin Pharm Ther*; 32(6):617-624.
- Breger uv, peng jBand Hedier MA(2000):** The membrane transporter families in mammals in the kidney, third edition chapter 4, PP.107-138.
- Bruder JM, Guise TA, Mundy GR, Felig P, Frohman LA (2001):** Mineral metabolism in: *Endocrinology and metabolism*, Fourth Edition, Chapter 22, pp.1079-1159.
- Brown AJ (2007):** Vitamin D analogs for secondary hyperparathyroidism: what does the future hold? *J Steroid Biochem Mol Biol* ;103(3-5):578-83.
- Bugeja A, Dacouris N, Thomas A, et al: Incenter nocturnal Hemodialysis(2009) :** another option in the management of chronic kidney disease . *Clin J Am Soc Nephrol*;4:778-783.

- Cannata-Andia JB & Rodriguez-Garcia M (2002):** Hyperphosphatemia as a cardiovascular risk factor-How to manage the problem. *Nephrol Dial Transplant*;17 Suppl 11:16-9.
- Cannella G, Messa P (2006):** Therapy of secondary hyperparathyroidism to date: vitamin D analogs, calcimimetics or both? *J Nephrol*; 19(4): 399-402.
- Carlson AP, Yonas HM, Turner PT (2007):** Disorders of tumoral calcification of the spine: illustrative case study and review of the literature. *J Spinal Disord Tech*;20(1):97-103.
- Carter WB, Carron JD, Ramadan HH, Talavera F, Calhoun KH, Slack CL, Meyers AD (2005):** Parathyroid Physiology; 209-234.
- Chabardes D, Imbert M, Clique A (2005):** PTH sensitive adenylyl cyclase activity in different segments of the rabbit nephron. *Pflugers Arch*; 354:229.
- Chertow G, Dillon M, Amin N, Bommer J, Burke S (2001):** Sevelamer is more effective at controlling disorders of mineral metabolism than calcium-based phosphate binders in hemodialysis patients. *J Am Soc Nephrol* (9)12:195A.
- Chertow GM, Burke SK, Raggi P (2002):** The Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney Int* 62 : 245 –252.

Christakos S, Dhawan P, Shen Q, Peng X, Benn B, Zhong Y (2006): new insights into the mechanisms involved in the pleiotropic action of 1,25dihydroxyvitamin D₃. Ann NY Acad Sci 1068: 194-203.

Coladonato JA (2005): Control of Hyperphosphatemia among Patients with ESRD. J Am Soc Nephrol 16: 107- 114.

Coladonato JA, Szczech LA, Friedman EA, Owen WF Jr (2002): Does calcium kill ESRD patients? The skeptic's perspective. Nephrol Dial Transplant 17 : 229–232.

Cole DE, Webb S and Chan PC (2007): Update on parathyroid hormone: New tests and new challenges for external quality assessment. Clin Biochem; 40(9-10):585-590.

Cozzolino M, Galassi A and Brancaccio D (2007): The bone-vasculature-axis interaction: new insights into the pathogenesis of vascular calcification. G Ital Nefrol ; Oct;24(5):409-14.

Culleton BF, Walsh M, Klarenbach SW, et al (2007) : Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life ., JAMA ; 298: 1291-1299.

Cunningham J (2004): New Vitamin D analogues for osteodystrophy in chronic kidney disease. Pediatric Nephrol ;19(7):705-8.

- Cunningham J, Danese M, Olson K, Klassen P, Chertow GM (2005):** Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture and health-related quality of life in secondary hyperparathyroidism. *Kidney Int* ;68(4):1793-800.
- Cupisti A, D'Alessandro C, Baldi R, Barsotti G (2004):** Dietary habits and counseling focused on phosphate intake in hemodialysis patients with hyperphosphatemia. *J Ren Nutr* 14 : 220 –225.
- Damment SJP, Gill M (2003):** The pharmacokinetics and tissue distribution of lanthanum carbonate (Fosrenol), a new non-aluminum, non-calcium phosphate binder [Abstract]. *J Am Soc Nephrol* 14 : 204A .
- Damment SJP, Webster I (2003):** The pharmacology of lanthanum carbonate: A new non-aluminum-, non-calcium phosphate binder [Abstract]. *J Am Soc Nephrol* 14 : 204A .
- Davies M and Adams PH (2003):** The continuing risk of vitamin D intoxication. *Lancet*; ii, 621-3.
- Defotes LJ, Bilezikian JP, Marcus R, and Levien A (2001):** Immunoassay for PTH and PTHrp in: The parathyroids, Second Edition, Chapter 9, pp.143-165.
- Delmez JA (1996):** Magnesium carbonate as a phosphorus binder: a prospective, cross over study. *Kidney Int*;49:163-167.

- Drezner MK, Bilezikian JP, Raisz LG, Rodan GA (2002) :**
phosphorus hemostasis and related disorder in:
Principles of bone biology, second Edition, chapter
22,pp.321-338.
- Eifinger F, Wahn F, Querfeld U, Pollok M, Gevarghez A,
Kriener P, Gronemeyer D (2000):** Coronary artery
calcifications in children and young adults treated with
renal replacement therapy. *Nephrol Dial Transplant.* ;
15(11): 1892-4.
- El-Amm JM, Doshi MD, Singh A, Migdal S, Morawski K,
Sternbauer D, Cincotta E, West MS (2007):**
Preliminary experience with cinacalcet use in persistent
secondary hyperparathyroidism after kidney
transplantation. *Transplantation.* 15;83(5):546-9.
- Elot S, Van Biesen W, Dhondt A, et al (2007) :** Im pact of
hemodialysis duration on the removal of uremic
retention solutes, *Kidney Int* 2;73:756-770.
- Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y:**
Superior dialytic clearane of B2- microglobulin
and P – vresol by high – flux hemodialysis as
compared to peritoneal dialysis . *Kidney
Int*2006 ;70-749-799.
- Evenpoel (2007):** Beneficial effects of sevelamer. *Kidney Int*;
71:376-9.

- Fareese S, Budmiger R, Aregger F, et al :** Effect of transcutaneous electrical muscle stimulation and passive cycling movements on blood pressure and removal of urea and phosphate during hemodialysis. *Am J Kidney Dis* 2008;52:745-752.
- Feliciani A , Riva MA , Zerbvi S, et al :** New strategies in Hemodiafiltration (HDF): prospective comparative analysis between online mixed HDF and mid – dilution HDF. *Nephrol Dial Transplant* 2007; 32:1672-1679.
- Freemont AJ (2007):** Lanthanum carbonate. *Drugs Today (Barc)*;43(4):275.
- Freiberg JM and Kinsella J (2002):** Glucocorticoids increase the Na⁺-H⁺ exchange and decrease the Na gradient dependent phosphate uptake system in renal brush border membranes vesicles. *Proc Natl Acad Sci USA*;79:4932.
- Friedman EA (2005):** An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic kidney disease. *Kidney Int Suppl*; (96):S2-6.
- Ganish SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK(2001):** Association of elevated serum PO₄, Ca×PO₄ product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. *J Am Soc Nephrol* 12 : 2131 –2138.

Gmaj P and Murer H (2006): Cellular mechanisms of inorganic phosphate transport. *Physiological Reviews*; 66,36-70.

Gonella M, Ballanti P, Della Rocca C, Calabrese G, Pratesi G, Vagelli G, Mazzotta A, Bonucci E (1998): Improved bone morphology by normalizing serum magnesium in chronic hemodialyzed patients. *Miner Electrolyte Metab* 14 : 240 –245.

Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000): Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. *N Engl J Med*. 18;342(5):1478-83.

Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW (2002): The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. *J Am Soc Nephrol* 13 : 1017 – 1024.

Gotch FA, Panlilio F, Sergeyeva O, Rosales L, Folden T, Kaysen G, Levin NW : Effective diffusion volume flow rate (Ae) for urea , creatinine , and inorganic phosphorus (Qeud Qecr, Qeip) during hemodialysis . *Semin Dial* 2003; 16:474-476.

- Gotch FA, Panlilio F, Sergeyeva O, Rosales L, Folden T, Kaysen G, Levin NW(2003):** A kinetic model of inorganic phosphorus mass balance in hemodialysis therapy. *Blood Purif* 21 : 51 –57.
- Guerin AP, London GM, Marchais SJ, Metivier F (2000):** Arterial stiffening and vascular calcifications in end-stage renal disease. *Nephrol Dial Transplant*; 15(7): 1014-21.
- Gutzwiller JP, Schneditz D, Huber RA (2002):** Estimating phosphate removal in hemodialysis: an additional tool to quantify dialysis dose. *Nephrol Dial Transplant*; 17:1037-44.
- Gutzwiller JP, Schneditz D, Huber AR, Schindler C, Garbani E, Zehnder CE(2003):** Increasing blood flow increases Kt/V(urea) and potassium removal but fails to improve phosphate removal . *Clin Nephrol* ; 59: 130-136.
- Haas JA, Bernt T and Knox FG (2001):** Nephron heterogeneity of phosphate reabsorption. *Am J of Physiology*; 234, F 287-90.
- Imran S, Abdul Halim, Ashfaq A, Mohsin S, MuhammedK, Dilshad A, Humera I (2008):** Comparison of calcium acetate with calcium carbonate as phosphate binder in patient on maintenance hemodialysis. *J AyubMed Coll Abbotabad*;19(4).

References

- Indridason OS, Quarles LD (2000):** The Durham Renal Osteodystrophy Study Group: Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. *Kidney Int* 57 : 282 –292.
- Isidro B. Salusky (2001):** symposium of Extraskelatal Calcification in Uremia: Cardiovascular Implications. World congress ASN /ISN October.
- Jono S, Mackee MD, Murry CE, Shioi A, Nishizawa, Mori K, Morii H, Giachelli CM (2000):** Phosphate regulation of vascular smooth muscle cell calcification. *Circ Res*.87:E10-E17.
- Joy MS and Finn WF (2004):** The new phosphate-binding agent lanthanum carbonate: Further evidence of long-term (2-year) efficacy and safety [Abstract]. *J Am Soc Nephrol* 15 : 763A .
- Joy MS, Finn WF (2001):** Results of a randomized phase III, dose-titrating, parallel group study of lanthanum carbonate for reduction and maintenance of serum phosphate in chronic hemodialysis patients [Abstract]. *J Am Soc Nephrol* 12 : 388A .
- Joy MS, Finn WF (2003):** The LAM-302 Study Group: Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. *Am J Kidney Dis* 42 : 96 –107.

- Jüppner HW, Gardella TJ, Brown EM (2000):** Parathyroid hormone and parathyroid hormone-related peptide in the regulation of calcium homeostasis and bone development. In *Endocrinology*, edn 4, vol 2, pp 969–998. Eds LL DeGroot & JL Jameson. Philadelphia: Elsevier.
- Kalantar-Zadeh K, et al (2006):** Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. *Kid Int*; 70(4):771-780.
- Kuhlmann MK (2010):** phosphate elimination in modalities of hemodialysis and peritoneal dialysis. *Blood Purif* ;29:137-144.
- Kato H and Mitarai T (2007):** Several PTH assay and the problem. *Clin Calcium*;17(5):745-51.
- Katopodis KP, Chala A, Kolioussi E, Takouli L, Kalaitzidis R, Theodorou J, Siamopoulos KC (2005):** Role of the dialyzer membrane on the overall phosphate kinetics during hemodialysis. *Blood Purif* ;23(5):359-64.
- Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL (2005):** Serum phosphate levels and mortality risk among people with chronic kidney disease. *J Am Soc Nephrol* 16:1315-1333.
- Ketteler M, Gross ML, Ritz E (2005):** Calcification and cardiovascular problems in renal failure. *Kidney Int Suppl* ;94:S120-S 127.

Ketteler (2007): Sevelamer and fetuin A serum levels. ASN abstract.

Kim J, Pisoni RL, Danese MD, Satayathum S, Klassen P, Young EW (2003): Achievement of proposed NKF–K/DOQI bone metabolism and disease guidelines: Results from the dialysis outcomes and practice patterns study (DOPPS) [Abstract]. J Am Soc Nephrol 14 : 269A –270A.

Kossmann RM, Gonzales A, Callan R, Ahmad S: Increased efficiency of hemodialysis with citrate dialysate: a prospective controlled study. Clin J Am Soc Nephrol 2009;4:1403-1404.

Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG (2005): The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant; 20(7):1311-4.

Kuhlmann MK (2006): Management of hyperphosphatemia. Heamodial Int;10(4):338-45.

Kuhlmann MK, Hoechst S, Landthaler 1(2007) : patient empowerment in the management of hyperphosphatemia . Int J ArtifOrgans 30:1008- 1013.

Kuro-O M (2006): Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism.Curr Opin Nephrol Hypertens; 15(4):437-41.

Lacour B, Lucas A, Auchere D, Ruellan N, De Serre Patey NM, Drueke TB (2005): Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. *Kidney Int* 67 : 1062 –1069.

Lee DBN, Welling MW and Brautbar N (2002): Intestinal phosphate absorption: influence of vitamin D and non-vitamin D factors. *American Journal of Physiology*; 250,G369-73.

Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD (2005): Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. *Semin Dial* ;18(4):353-4

Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ (2003): The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. *Kidney Int* 63 : 248 –254.

Lindsay RM, Heidenheim P, Leitch R, Ryan H, Kroeker A, Peters K, Workentin L, Nesrallah G, Prakash S, Kortas C (2001): The Daily/Nocturnal Dialysis Study Group: Short daily versus long nocturnal hemodialysis. *ASAIO* 449 –455.

Lindsay RM , Alhejaili F, Nesrallah G, Leitch R, Clement L ,

- Heidenheim AP, Kotas C:** Calcium and phosphate balance with quotidian hemodialysis . Am J Kidney Dis 2003; 42 (suppl 1) : 24-29.
- Liu and Quarles (2007):** How FGF-23 works! J Am Soc Nephrol; 18:1637-27.
- London GM, Pannier B, Marchais ST (2000):** Calcification of aortic valve in the dialyzed patients. J Am Soc Nephrol;11:778-783.
- Maduell F, Navarro V, T Gorregrosa E, Rius A, Dicenta F, Cruz MC , Ferrero JA(2003):** Change from tghree times a week on – line hemodialtration to short daily on – line hemodiafiltration . KidneyInt ; 64: 305-313.
- Malluche HH, Gaugere MC, Wang G, Demment SJP, Webster I (2004b):** No evidence of osteomalacia in dialysis patients treated with lanthanum carbonate up to 5 years [Abstract]. J Am Soc Nephrol 15 : 270A .
- Malluche HH, Gaugere MC, Wang G, Finn WF (2004a):** Lanthanum carbonate and bone: No adverse effects observed after 1 year of treatment in a randomized, comparator-controlled trial [Abstract]. J Am Soc Nephrol 15 : 271A .
- Manns B, Stevens L, Miskulin D, Owen WF Jr, Winkelmayer WC, Tonelli M (2004):** A systematic review of Sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 66 : 1239 –1247.

- Maroulis JC, Fourtounas C, Siasos N, Habeos I (2006):** Calciphylaxis: a complication of end-stage renal disease improved by parathyroidectomy. *Hormones(Athens)* ;5(3):210-3.
- Mathew S, Davies M and Hruska KA (2006):** Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease. *Euro J Clin Invest*; 36 Suppl 2:43-50.
- Matsumoto T, Kubodera N (2007):**ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects. *J Steroid Biochem Mol Biol*;103(3-5):584-6.
- Michaut P, Prie D, Amiel C and Friedlander G (2004):** New role for an old drug: dipyridamole for renal phosphate leak. *New England Journal of Medicine*; 331,58-9.
- Minutolo R, Bellizzi V, Cioffi M, Iodice C, Giannattasio P, Andreucci M, Terracciano V, Di Iorio BR, Conte G, De Nicola L(2002):** Postdialytic rebound of serum phosphorus: Pathogenetic and clinical insights. *J Am Soc Nephrol* 13 : 1046 –1054.
- Minutolo R, Bellizzi ,VB, Cioffi M,et al :** Postdialytic rebound of serum phosphorus: pathognetic and clinical insights . *J Am Soc Nephrol* 2002 ;13: 1046-1054.
- Mitnick P.D., Goldfarb S, Slatopolsky E., Lemann J., Gray R.W. and Agus Z.S. (2000):** Calcium and phosphate metabolism in tumoral calcinosis. *Anuals of Internal Medicine*, 92, 482-7.

- Miyamoto K, Segawa H, Ito Metal(2004):** Physiological regulation of renal sodium dependant phosphate cotransporter. Jpn J physiol.54:93-102.
- Mochizuki T, Naganuma S, Tanaka Y, Iwamoto Y, Ishiguro C, Suda A, Akiba T (2007):** Prospective comparison of the effects of maxacalcitol and calcitriol in chronic hemodialysis patients with secondary hyperparathyroidism: a multicenter, randomized crossover study. Clin Nephrol ;67(1):12-9.
- Monabally J, Zachee P, Verberckmoes R and Boogaerts MA (2004):** Transient acute renal failure due to tumor-lysis induced severe phosphate load in a patient with Burkitt's lymphoma. Clinical Nephrology;66,42-50.
- Monge M, Shahapuni I, Oprisiu R and Fournier A (2006):** Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients. Nat Clin Pract Nephrol ;2(6):326-36.
- Morion AR, Hercz G and Coburn JW (1990):** Control of hyperphosphatemia in chronic renal failure. Seminars in dialysis 3: 219-223.
- Mucsi, I Hercz G, Uldall R, et al (1998) :** Contorl of serum phosphate without any phosphate binders in patients treated with noturnal hemodialysis , Kidney In ; 53:1399- 1404.
- Murer H, Hernando N, Forster I et al (2003):** Regulation of Na/Pi trasporter in the proximal tubule .Physiol 65:531- 542.

Nakanishi S and Fukagawa M (2001): PTH assay: new and future. Clin Calcium ;11(8):1019-23.

Nasri H (2006): Linkage of elevated CaxPO₄ product with inflammation in maintenance hemodialysis patients. Minerva Urol Nefrol; 58(4):339-45.

National Kidney Foundation(2003a): K/DOQI definition and classification of stages of chronic kidney disease. Am J Kidney Dis 42 : S46 –S75.

National Kidney Foundation (2003b): K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 : S1 – S201.

Naveh-Many T and Nechama M (2007): Regulation of parathyroid hormone mRNA stability by calcium, phosphate and uremia. Curr Opin Nephrol Hypertens ;16(4):305-10.

Negri AL (2005): Vascular calcifications in chronic kidney disease: are there new treatments? Curr Vasc Pharmacol ;3(2)181-4.

Nicholas Borgert (2006): Diagnostic and Treatment Options for Kidney Disease Expand. Clinical Lab Product; June .

Nolan CR (2005): Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines. Kidney Int Suppl ;(96):S7-14.

- Noordzij M , Korevaar JC , Bos WJ , et al(2006) :** mineral metabolism and cardiovascular morbidity and mortality risk : peritoneal dialysis patients compared with hemodialysis patients *Nephrol Dial Transplant* ; 21:2513-2520.
- Olson JC, Edmundowicz D, Recker DJ, Kuller LH, Orchard TJ (2000):** Coronary calcium in adults with type 1 diabetes: a stronger correlate of clinical coronary artery disease in men than in women.
- Ohashi N, Uematsu T, Nagashima S, Kanamaru M, Togawa A, Hishida A, Uchida E, Akizawa T (2004):** The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis and on the day without haemodialysis. *Br J Clin Pharmacol*; 57(6):726-34.
- Pierratos A, Ouwendyk M , Francoeur R, Vas S, Raj DS , Ecclestone AM, Langos V, Uldall R (1998):** Nocturnal hemodialysis: three – year experience *J Am Soc Nephrol* ; 9:859-868.
- Potts JT (2005):** Parathyroid hormone: past and present. *Journal of Endocrinology*: 187, 311-325.
- Prie D, Urena Torres P, Fredlander G (2009) :** Latest Findings in phosphate homeostasis. *Kidney int*75:882- 229.

References

Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA (2003): The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. *J Am Soc Nephrol* 14 : 575 –583.

Qunbi W et al. (2004):Comparing phosphate binders efficacy. *Kidney Int*; 65:1914-1926.

Quinn SJ, Kifor O, Trivedi S (2002): Sodium and ionic strength sensing by the calcium receptor. *J Biol Chem* Jul 31; 273(31): 19579-86.

Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, Pelham RW, Cleveland MVB, Muenz LR, He DY, Nolan CR (2004): Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). *Kidney Int* 65 : 1914 –1926

Raggi P, Burke S, Dillon M, Amin N, Boomer J (2001): Sevelamer attenuates the progression of coronary and aortic calcification compared with calcium-based phosphate binders. *J Am Soc Nephrol* (9) 12:239A.

Raine AE (1995): Hypertension and ischaemic heart disease in renal transplant recipients. *Nephrol Dial Transplant*; 10 Suppl 1:95-100. Review. No abstract available.

Ramsamy I (2006): Recent advances in physiological calcium homeostasis. *Clin chem lab med*.44:237-273.

Razzaque MS and Lanske B (2007): The emerging role of the fibroblast growth factor-23-klotho axis in renal

regulation of phosphate homeostasis. J
Endocrinol;194(1):1-10.

Reuss L, Seldin DW, Giebisch G (2000): Basic mechanism of
ion transport in the kidney. third edition, chapter
3,pp.85- 106.

Reynolds et al. (2005): Fetuin A and vascular calcifications. J
Am Soc Nephrol; 16:2920-30.

Rippe B , Benturolio D , Simonsen O, de Arteaga J (2004):
Fluid and electrolyte transport across the
peritoneal membrane during CAPD according to
the three – pore model . Perit Dial Int ;24:10-27.

Ritz E (2005): The clinical management of
hyperphosphatemia. J Nephrol; 18(3):221-8.

Rizzoli R, Fleisch H and Bonjour JP (2004): Role of 1,25-
dihydroxyvitamin D₃ on intestinal phosphate
absorption in rats with a normal vitamin D supply. J of
Clin Invest; 60,639-47.

Rocha AS, Magaldi JB and Kokko JP (2005): Calcium and
phosphate transport in isolated segments of rabbit
Henle's loop. J of Clinical Invest; 59,975-83.

Sac M (2002): Fosrenol (lanthanum carbonate) is well
tolerated in patients requiring hemodialysis: Results of
a phase I clinical trial [Abstract]. J Am Soc Nephrol
13 : 386.

Salusky IB, et al (2003): Similar predictive value of bone
turnover using first and second generation

immunometric PTH assays in pediatric patients treated with peritoneal dialysis. *Kid Int*; 63:1801-1808.

Schmitt CP, Borzych D, Nau B, et al (2009) : Dioalytic phosphate remobvale : a modifiable measure of dialysis efficacy in automate peritoneal dialysis . *Peri Dial In* ; 29:465-4

Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K (2000): Morphology of coronary atherosclerosis lesions in patients with end-stage renal failure. *Nephrol Dial Transplant*; 15(2):218-23.

Sedalcek M , Dimaano F, Uribarri J (2000) : Relationship between phosphorus and creatinine clearance in peritionela dialysis ; clinical implication . *Am J KidneyDis* ; 36 :1020-1224

Shahapuni I, Mansour J, Harbouche L, Maouad B, Benyahia M, Rahmouni K, Oprisiu R, Bonne JF, Monge M, El Esper N (2005): How do calcimimetics fit into the management of parathyroid hormone, calcium and phosphate disturbances in dialysis patients. *Semin Dial*; 18(3): 226-38

Shahapuni I, Monge M, Oprisiu R, Mazouz H, Westeel PF (2006): Renal indications of calcimimetics. *Nat Clin Pract Nephrol*; 2(6):316-25.

Shigematsu T, Sakaguchi T, Orita H (2007): Phosphate binder up to date. *Clin Calcium*;17(5):772-8. .

Shimizu M, Carter PH, Khatri A, Potts JT Jr & Gardella TJ (2001): Enhanced activity in parathyroid hormone-

(1–14) and (1–11): novel peptides probing ligand–receptor interactions. *Endocrinology* 142 3068–3074.

Shimizu M, Potts JT Jr & Gardella TJ (2000): Minimization of parathyroid hormone (PTH): novel amino-terminal PTH fragments with enhanced potency for the agonist-binding domain of the PTH-1 receptor. *Journal of Biological Chemistry* 275 21836–21843.

Shimizu M, Shimizu N, Tsang JC, Petroni BD, Khatri A, Potts JT Jr & Gardella TJ (2002): Residue 19 of the parathyroid hormone (PTH) modulates ligand interaction with the juxta membrane region of the PTH-1 receptor. *Biochemistry* 41 13224–13233.

Siegfrie G, Vrtovsnik F, Prie D, Amiel C and Friedlaner G (2005): Parathyroid hormone stimulates ecto-5-nucleotidase activity in renal epithelial cells: role of protein kinase C. *Endocrinology*; 136,1267-75.
Invest 97 : 2534 –2540.

Spalding EM, Chamney PW, Farrington K : phosphate Kinetics during hemodialysiss: evidence for biphasic regulation . *Kidney Int* 2002; 61: 655 – 667.

Stewart J (2002): Administration of a novel phosphate binder, Fosrenol with food is associated with good tolerability and low systemic absorption [Abstract]. *J Am Soc Nephrol* 13 : 386.
Intern Med; 34:908-12.

Takeda E, TaketaniY, Sawada N, Sato T, Yamamoto H (2004): The regulation and function of phosphate in

the human body. *Biofactors*.21:345-355.

Thakker RV & Jüppner H (2005): Genetic disorders of calcium homeostasis caused by abnormal regulation of parathyroid hormone secretion or responsiveness. In *Endocrinology*, edn 5, vol 2, pp 1511–1531. Eds LL DeGroot & JL Jameson. Philadelphia: Elsevier.

Tonelli M , Wang W , Hemmelgarn B, et : Phosphate removal with several thrice weekly dialysis methods in overweight he modialysis patients . *A J Kideny Dis* 2009.

Torres PU (2006): Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. *J Ren Nutr*; 16(3):253-8.

Uemura K, Kakota T and Saito A (2007): Relationship between sevelamer HCl and vascular calcification. *Clin Calcium*;17(3):392-8.

Urena P, Legoupil N, de Vernejoul MC (2005): Calcimimetics, mechanism of action and therapeutic applications. *Presse Med*.10; 34(15):1095-100.

Vaithilingam 1, Polkinghorne KR, Atghins RC, Kerr PG: Time and exercise improve phosphate removlain hemodialysis patients. *Am J Kidney Dis* 2004;43:85-89.

Van Abel M, Hoenderop JGJ, Van Leeuwen JPTM, Bindels RJM (2003): Down regulation of Ca²⁺ transporters in kidney and duodenum by calcimimetic

compound NPS R-467 [Abstract]. J Am Soc Nephrol 14 : 459A .

Wasserman RH and Taylor AN (2000): Intestinal absorption of phosphate : Effects of vitamin D3 and other parameters. Journal of Nutrition; 103,586-99.

Watanabe Y (2004): Vitamin D supplementation for chronic kidney disease according to the guideline issued by DOQI. Clin Calcium;14(5):778-85.

Yoshida H and Yokoyama K (2007): Mechanism, imaging technique and therapy for vascular calcification in patients of chronic kidney disease. Clin Calcium;17(5):726-33.

Yuen D, Richardson RM , Chan CT (2005): Improvements in phosphate control with short daily in – center hemodialysis. Clin Nephrol ; 64: 364-370.

Zehnder C, GutZwiller JP, Renggli K : hemodifiltration a new treatment option for hyperphosphatemia in hemodialysis patients. Clin Nephrol 1999;52: 152-159.

.

